<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Revenue Forecast on FinanClub</title>
    <link>https://finan.club/tags/revenue-forecast/</link>
    <description>Recent content in Revenue Forecast on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 08 Aug 2023 07:17:40 +0000</lastBuildDate><atom:link href="https://finan.club/tags/revenue-forecast/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title> INFY</title>
      <link>https://finan.club/us/infy/</link>
      <pubDate>Tue, 08 Aug 2023 07:17:40 +0000</pubDate>
      
      <guid>https://finan.club/us/infy/</guid>
      <description>score:825
Chances: Infosys benefits from strong demand for cloud, data analytics, IoT, and security products amid the ongoing digital transformation wave. Optimism returns for India&amp;rsquo;s IT companies as easing odds of a US recession and the emergence of AI as a revenue source drive a rebound in stocks.</description>
    </item>
    
    <item>
      <title> GILD</title>
      <link>https://finan.club/us/gild/</link>
      <pubDate>Tue, 08 Aug 2023 07:17:02 +0000</pubDate>
      
      <guid>https://finan.club/us/gild/</guid>
      <description>score:724
Chances: Gilead Sciences expects a third of sales to come from its cancer treatments by 2030, driving optimism and stock price movement. Gilead Sciences is focused on developing therapies for life-threatening infectious diseases and expanding its portfolio to include pulmonary, cardiovascular diseases, and cancer treatments.</description>
    </item>
    
    <item>
      <title> MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Tue, 08 Aug 2023 07:02:27 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:1154
Chances: Merck reported stronger-than-expected Q2 earnings and raised its 2023 guidance. Keytruda cancer-drug sales drove better-than-expected Q2 revenue and a raised full-year sales forecast. Merck&amp;rsquo;s top-selling products, Keytruda and HPV vaccine Gardasil, experienced strong demand. Cleveland Clinic has started enrolling subjects in a treatment arm evaluating Anixa&amp;rsquo;s breast cancer vaccine with Keytruda.</description>
    </item>
    
  </channel>
</rss>
